ivosidenib
servier
['ivosidenib', 'mds']
today at #asco22, check out dr. david sallman's poster #284 to see results from a phase-1 dose-escalation and expansion substudy looking at ivosidenib in patients with idh1-mutant relapsed/refractory #mds. view abstract: 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19.